An observational study in Rectal Cancer, sponsored by Sun Yat-sen University. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-12.
Sponsored by Sun Yat-sen University · Observational
The purpose of this study was to compare the long-term oncology outcomes and specimen quality of taTME and laTME in the treatment of middle and low rectal cancer by a large sample cohort. At the same time, the local recurrence following a primary rectal cancer resection was analyzed to respond to the concerns about the event of the national suspension for TaTME due to the high local recurrence rate in Norway.
Laparoscopic surgery is considered to have better visualization for more accurate separation and further injury reduction than open surgery. However, the oncology outcomes are still controversial. Especially in the challenging patients who have narrow and deep pelvic, the disadvantage that it is difficult to obtain high-quality resected specimens during laparoscopic TME (laTME) surgery is considered to be magnified. It is considered transanal total mesorectal excision (taTME) is an alternative method to solve this "old problem". However, as a new technology that has been around for only 10 years, the applicability of taTME worldwide needs to be further proved in long-term oncology. This prospective cohort study aimed to compare taTME surgery to laTME surgery for mid and low-rectal cancer on long-term oncology outcomes from a single, experienced Chinese center that was an early adopter of taTME.
1,762 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.
This study's enrollment of 2,502 is above the median of 160 across 413 observational studies indexed under Rectal Neoplasms.
Browse Rectal Neoplasms studies →Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Low-mid rectal cancer within Stage III.
Exclusion Criteria:
patients who underwent transanal total mesorectal excision
Procedure: transanal total mesorectal excision
patients who underwent laparoscopic total mesorectal excision
transanal TME
Also known as: laparoscopic total mesorectal excision
Overall survival rate
Time frame: 5 years after the surgery
disease-free survival ratev
Time frame: 5 years after the surgery
Local recurrence rate
Local recurrence was defined as radiologic or histopathologic evidence of any recurrent disease deposit located in the pelvis in the prior area of dissection following a primary rectal cancer resection, with or without distal metastasis
Time frame: 3 years after the surgery
Cancer special survival rate
Cancer special survival was defined as the time from the date of primary rectal cancer resection to the date of death caused by rectal cancer.
Time frame: 5 years after the surgery
Quality of the mesorectum specimen
The quality of the resected mesorectum was classified into three grades: (a) incomplete, (b) nearly complete, and (c) complete
Time frame: 30 days after the surgery
CRM status
The CRM was regarded as positive if the tumor distance or malignant lymph node to CRM was ≦1 mm.
Time frame: 30 days after the surgery
DRM status
The DRM was regarded as positive if it was microscopically involved by or ≦1 mm from the tumor margins.
Time frame: 30 days after the surgery
No study locations are listed for this record.
Plan to share: Undecided — The data can be obtained with a proper request.
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-sen University